We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Feature

'Revolving Door' At DEA Faces Scrutiny In Opioid MDL

Law360 (March 1, 2018, 11:28 PM EST) -- The U.S. Drug Enforcement Administration’s resistance to divulging information about opioid sales as part of multidistrict litigation is generating fresh scrutiny of its “revolving door” relationship with drug companies and law...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.